Metis TechBio, a Hong Kong-listed tech firm specializing in drug design, announced a significant development on Tuesday. The company has formed a pivotal agreement with Boulevard Bio, a biotechnology firm based in the United States, granting it exclusive worldwide rights to develop, produce, and market Metis TechBio's novel autoimmune drug, MTS-128.This agreement could be worth up to $1.6 billion, marking a significant step in the field of biotechnology. The deal reflects a growing trend in collaboration between U.S. and Chinese tech companies, even as Beijing intensifies its scrutiny of international technology contracts involving potentially sensitive innovations.This partnership underscores the continued…